請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55656
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 周綠蘋(Lu-Ping Chow) | |
dc.contributor.author | Chun-Yao Wang | en |
dc.contributor.author | 王俊堯 | zh_TW |
dc.date.accessioned | 2021-06-16T04:15:21Z | - |
dc.date.available | 2019-10-09 | |
dc.date.copyright | 2014-10-09 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-20 | |
dc.identifier.citation | 1. Cheng, J.W. and Y. Lv, New progress of non-surgical treatments for hepatocellular carcinoma. Medical Oncology, 2013. 30(1).
2. Bosch, F.X., et al., Primary liver cancer: Worldwide incidence and trends. Gastroenterology, 2004. 127(5, Supplement 1): p. S5-S16. 3. Wu, Q., et al., Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget, 2013. 4(11): p. 1999-2009. 4. Ascha, M.S., et al., The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology, 2010. 51(6): p. 1972-1978. 5. Subramaniam, S., R.K. Kelley, and A.P. Venook, A review of hepatocellular carcinoma (HCC) staging systems, in Chinese Clinical Oncology. 2013. 6. Lasham, A., et al., YB-1: oncoprotein, prognostic marker and therapeutic target? Biochemical Journal, 2013. 449(1): p. 11-23. 7. Aoudjit, F. and K. Vuori, Integrin signaling in cancer cell survival and chemoresistance. Chemotherapy research and practice, 2012. 2012. 8. Subramaniam, N., B. Hiremath, and A. Pujar, Metastasis of diffuse hepatocellular carcinoma to an extremely unusual site. BMJ Case Reports, 2013. 9. Bruera, G., et al., Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice. BioMed Research International, 2014. 2014: p. 11. 10. Beasley, R.P., et al., HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS: A Prospective Study of 22 707 Men in Taiwan. The Lancet, 1981. 318(8256): p. 1129-1133. 11. Llovet, J.M., J. Fuster, and J. Bruix, The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplantation, 2004. 10(S2): p. S115-S120. 12. Seeff, L.B., Introduction: The burden of hepatocellular carcinoma. Gastroenterology, 2004. 127(5, Supplement 1): p. S1-S4. 13. Gambarin-Gelwan, M., et al., Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol, 2000. 95(6): p. 1535-1538. 14. Pawlik, T.M., et al., Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transplantation, 2005. 11(9): p. 1086-1092. 15. Chow, A.K.M., et al., The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance. Plos One, 2013. 8(11). 16. Jilaveanu, L.B., et al., Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel. Plos One, 2013. 8(8). 17. Matter, M.S., et al., Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends. Journal of Hepatology, 2014. 60(4): p. 855-865. 18. Whittaker, S., R. Marais, and A.X. Zhu, The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 2010. 29(36): p. 4989-5005. 19. Torti, D. and L. Trusolino, Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med, 2011. 3(11): p. 623-36. 20. Berasain, C., Hepatocellular carcinoma and sorafenib: too many resistance mechanisms? Gut, 2013. 62(12): p. 1674-1675. 21. Pal, I. and M. Mandal, PI3K and AKT as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacologica Sinica, 2012. 33(12): p. 1441-1458. 22. Wu, Y., et al., Strong YB‐1 expression is associated with liver metastasis progression and predicts shorter disease‐free survival in advanced gastric cancer. Journal of surgical oncology, 2012. 105(7): p. 724-730. 23. van Roeyen, C.R.C., et al., Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities. Cell Communication and Signaling, 2013. 11. 24. Mantwill, K., et al., YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells. Journal of Translational Medicine, 2013. 11. 25. Maciejczyk, A., et al., Elevated Nuclear YB-1 Expression Is Associated with Poor Survival of Patients with Early Breast Cancer. Anticancer Research, 2012. 32(8): p. 3177-3184. 26. Kosnopfel, C., T. Sinnberg, and B. Schittek, Y-box binding protein 1-A prognostic marker and target in tumour therapy. European Journal of Cell Biology, 2014. 93(1-2): p. 61-70. 27. Didier, D.K., et al., Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proceedings of the National Academy of Sciences, 1988. 85(19): p. 7322-7326. 28. Kohno, Y., et al., Expression of Y-box-binding protein dbpC//contrin, a potentially new cancer//testis antigen. Br J Cancer, 2006. 94(5): p. 710-716. 29. Ladomery, M. and J. Sommerville, A role for Y-box proteins in cell proliferation. BioEssays, 1995. 17(1): p. 9-11. 30. Zhu, H., M. Bilgin, and M. Snyder, Proteomics. Annual Review of Biochemistry, 2003. 72(1): p. 783-812. 31. Aebersold, R. and M. Mann, Mass spectrometry-based proteomics. Nature, 2003. 422(6928): p. 198-207. 32. Apweiler, R., et al., Approaching clinical proteomics: current state and future fields of application in fluid proteomics, in Clinical Chemistry and Laboratory Medicine. 2009. p. 724. 33. Aebersold, R. and D.R. Goodlett, Mass Spectrometry in Proteomics. Chemical Reviews, 2001. 101(2): p. 269-296. 34. Ong, S.-E. and M. Mann, Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol, 2005. 1(5): p. 252-262. 35. Ong, S.-E. and M. Mann, A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat. Protocols, 2007. 1(6): p. 2650-2660. 36. MF, C. and S. D, Biological sequence motif discovery using motif-x. Curr Protoc Bioinformatics, 2011: p. Chapter 13:Unit 13.15-24. 37. Schwartz, D. and S.P. Gygi, An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets. Nat Biotechnol, 2005. 23(11): p. 1391-8. 38. Brooks, S.A., et al., Molecular interactions in cancer cell metastasis. Acta Histochemica, 2010. 112(1): p. 3-25. 39. Moritz, A., et al., AKT-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal, 2010. 3(136): p. ra64. 40. Carriere, A., et al., ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem, 2011. 286(1): p. 567-77. 41. Hsui, C.M., et al., Bufalin induces G2/M phase arrest and triggers autophagy via the TNF, JNK, BECN-1 and ATG8 pathway in human hepatoma cells. International Journal of Oncology, 2013. 43(1): p. 338-348. 42. Clevers, H. and R. Nusse, Wnt/β-Catenin Signaling and Disease. Cell, 2012. 149(6): p. 1192-1205. 43. Stratford, A.L., et al., Targeting p90 Ribosomal S6 Kinase Eliminates Tumor‐Initiating Cells by Inactivating Y‐Box Binding Protein‐1 in Triple‐Negative Breast Cancers. Stem Cells, 2012. 30(7): p. 1338-1348. 44. Brandt, S., et al., Cold shock Y-box protein-1 participates in signaling circuits with auto-regulatory activities. European Journal of Cell Biology, 2012. 91(6–7): p. 464-471. 45. Shibata, T., et al., Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. Molecular cancer therapeutics, 2013. 12(5): p. 737-746. 46. Gastaldi, S., P.M. Comoglio, and L. Trusolino, The Met oncogene and basal-like breast cancer: another culprit to watch out for. Breast Cancer Res, 2010. 12(4): p. 208. 47. Lasham, A., et al., YB-1, the E2F Pathway, and Regulation of Tumor Cell Growth. Journal of the National Cancer Institute, 2012. 104(2): p. 133-146. 48. Chatterjee, M., et al., The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Vol. 111. 2008. 3714-3722. 49. Imada, K., et al., Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression. Clin Cancer Res, 2013. 19(17): p. 4638-50. 50. Jurchott, K., et al., Identification of Y-Box Binding Protein 1 As a Core Regulator of MEK/ERK Pathway-Dependent Gene Signatures in Colorectal Cancer Cells. PLoS Genet, 2010. 6(12): p. e1001231. 51. Rocha, E.A., et al., Identification of a new Schistosoma mansoni SMYB-1 partner: putative roles in RNA metabolism. Parasitology, 2013. 140(9): p. 1085-1095. 52. Khan, M.I., et al., YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin. 2014. 2014. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55656 | - |
dc.description.abstract | 肝細胞癌(hepatocellular carcinoma, HCC)在全球癌症致死率排名第三,有九成都屬於原發性肝癌(Primary liver cancer),其中B型及C型肝炎病毒感染或是肝硬化的發展是造成HCC的主要元兇。由於末期肝細胞癌之腫瘤較具有侵略性且病人預後較差,因此治療末期肝癌的過程通常較為複雜,主要的治療方法為肝臟手術性之切除,但由於肝細胞癌末期病人常常有腫瘤細胞轉移以及肝功能不全等現象,因此大多數病人並不適用肝臟切除手術。近年來,多重激酶抑制劑蕾莎瓦(multi-kinase inhibitor)作為標靶藥物用來治療病人成為末期肝細胞癌症病人的另一治療選擇,此藥物對於末期肝細胞癌病人的存活率已有所提升。
在本研究中,我們利用質譜定量之技術結合SILAC(Stable Isotope Labeling of Amino acids in Cell culture)技術來分析比較處理蕾莎瓦前後之HuH7細胞,一共鑑定到了562個磷酸化蛋白,其中包含了2180條磷酸化胜肽(在蕾莎瓦處理下發現了72個表現量上升、116個表現量下降之磷酸化位點),接著使用motif-xR、STRING及IPAR分析軟體分析後,發現有些蛋白在蕾莎瓦處理下改變量有明顯增減者多屬於MAPK signaling pathway,其中一個表現量下降之蛋白為DNA結合蛋白Y-box binding protein 1(YB-1),由文獻資料得知這是一個同時會被MAPK signaling pthway 以及 PI3K/AKT signaling pathway所調控之下游轉錄因子,在眾多癌症中均有大量表現並與癌症發展以及抗藥性有關。在本研究中我們發現YB-1在HuH7細胞中被MAPK-ERK signaling pathway所調控,在U0126(MEK抑制劑)治療下其磷酸化表現量下降;意外的是我們發現YB-1磷酸化表現量在對sorafenib具有抗藥性之HuH7R細胞中高度上升,亦有文獻指出YB-1是AKT的受質,而由AKT磷酸化YB-1所影響之細胞功能尚不明朗。 根據本研究,YB-1在HuH7R細胞中是被PI3K/AKT signaling pathway所調控,細胞之侵襲能力(invasion)與爬行能力(migration)接隨著YB-1被抑制(knock down)而下降,藉由訊息傳導路徑以及功能分析,我們認為YB-1藉由調控PI3K/AKT/GSK3β signaling pathway來影響細胞之侵襲以及爬行能力,同時我們也找到了一些被YB-1所調控之下游分子如PI3K, P53和VEGFA可能對於細胞存活能力有所影響。 最後,我們確立了YB-1在HuH7及HuH7R細胞中截然不同的功能,其中YB-1在HuH7細胞中是被MAPK signaling pathway所調控,在HuH7R細胞中則是被另一條替代訊息傳導路徑PI3K/AKT signaling pathway所調控。藉由了解同一個分子在不同的條件下所扮演的角色,對於嶄新抗癌藥物的發展或是替代療法的選擇上將有所助益。 | zh_TW |
dc.description.abstract | Hepatocellular carcinoma(HCC) is now the third leading cause of cancer deaths worldwide, accounting for 90% of primary liver cancers. Most cases of HCC are secondary to either a viral hepatitis infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis). Advanced HCC is often a complex condition with highly aggressive tumor and poor prognosis to common therapies. The mainstay of therapy is surgical resection, but the majority of patients are not eligible because of tumor extent or underlying liver dysfunction. Recently, a therapeutic option for advanced HCC is the use of sorafenib, a muti-kinase inhibitor, which was showed to be able to increase survival in HCC patients.
In this study, we applied quantitative proteomics approach using nanoflow LC MS/MS in combination with SILAC technology to compare HuH7 and sorafenib treated HuH7 cells. Through phosphopeptide enrichment by titanium dioxide affinity column, a total of 2180 phosphopeptides from 562 phosphorylated proteins were identified. The SILAC based quantification described 72 up-regulated and 116 down-regulated phosphorylation sites upon sorafenib treatment. By using Motif-x, STRING and IPA analyses, we found that most proteins showing significant fold change under sorafenib treatment are involved in MAPK-ERK signaling pathway. One of the down-regulated proteins we found is the Y-Box binding protein 1(YB-1), which was reported as a transcription factor regulated by MAPK-ERK and PI3K-AKT signaling pathway. YB-1 is overexpressed in many cancers and associated with tumor progression and drug resistance. In this study we found that YB-1 is a downstream target of MAPK-ERK signaling cascade, its phosphorylation is decreased under U0126(MEK inhibitor) treatment. Surprisingly, we found that phosphorylation of YB-1 is increased in sorafenib- resistant cell line HuH7R. Recent studies indicated YB-1 as a direct substrate of AKT. The functional significance of AKT-mediated phosphorylation remains largely unknown. Based on our findings, YB-1 is regulated by PI3K/AKT signaling pathway instead of MAPK signaling pathway in HuH7R cell. Invasion and migration ability are decreased in YB-1-knock-down HuH7R cell. After signaling pathway and functional analysis, results indicated that YB-1 regulates cell invasion and migration ability through activation of PI3K/AKT/GSK3βsignaling pathway. We further identified some YB-1-regulated downstream genes like PI3K, P53 and VEGFA that may contribute to cell viability. In conclusion, we defined different roles of YB-1 in HuH7 and HuH7R cell. YB-1 is regulated by MAPK signaling pathway in HuH7 cell but it is regulated by an alternative signaling pathway, PI3K/AKT signaling pathway, in HuH7R cell. Understanding different regulation mechanisms of the same signal molecule at different circumstances may contribute to further development of novel anti-cancer drug and alternative therapies. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T04:15:21Z (GMT). No. of bitstreams: 1 ntu-103-R01442013-1.pdf: 3770870 bytes, checksum: 2dfb9fd4c95952b4c9ce3e6bc1d8ed37 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 摘要……………………………………………………………………………………I
Abstract……………………………………………………………………………III 縮寫……………………………………………………………………………………V 第一章 導論…………………………………………………………………………1 第一節 肝細胞癌………………………………………………………………1 1.1 肝癌……………………………………………………………………1 1.2 肝癌的致病因子及發病過程…………………………………………1 1.3 肝癌的診斷……………………………………………………………3 1.4 肝癌的分類……………………………………………………………4 1.5 肝癌的治療……………………………………………………………5 第二節 肝癌細胞中的訊息傳導路徑…………………………………………6 2.1 肝癌細胞中三大訊息傳導路徑………………………………………6 2.2 癌症基因依賴(Oncogene addiction)……………………………7 2.3 肝癌細胞中其他替代訊息傳導路徑…………………………………8 第三節 DNA結合蛋白Y-box binding protein 1(YB-1)………………………9 3.1 YB-1與癌症……………………………………………………………9 3.2 YB-1所參與之訊息傳導路徑及其重要性…………………………10 第四節 研究動機………………………………………………………………11 第二章 實驗材料…………………………………………………………13 第一節 細胞株…………………………………………………………………13 第二節 儀器及裝置…………………………………………………………13 第三節 酵素…………………………………………………………………14 第四節 抗體…………………………………………………………………14 第五節 試劑組與藥品………………………………………………………15 第六節 生物材料……………………………………………………………17 第七節 軟體與資料庫………………………………………………………17 第三章 實驗方法…………………………………………………………………18 第一節 肝細胞癌細胞株的培養……………………………………………18 1.1 培養基(medium)的配置……………………………………………18 1.2 細胞的培養……………………………………………………………18 1.3 細胞的計數……………………………………………………………18 第二節 蛋白質分析法…………………………………………………………19 2.1 蛋白質濃度測定(Bradford Protein-binding Assay)…………19 2.2 十二烷基硫酸鈉-聚丙烯醯胺膠體電泳分析(SDS-PAGE)…………19 2.3 西方點墨法(western blotting)……………………………………20 第三節 小髮夾RNA(shRNA)抑制目標基因…………………………………22 3.1 菌株培養……………………………………………………………22 3.2 含shRNA之中量質體DNA萃取………………………………………22 3.3 含有shRNA枝慢病毒製備……………………………………………24 3.4 以包覆shRNA之慢病毒感染肝癌細胞株……………………………24 3.5 抗生素的篩選…………………………………………………………24 第四節 細胞培養中標定穩定同位素胺基酸(Stable Isotope Labeling of Amino acids in Cell Culture-SILAC)………………………………25 第五節 溶液內酵素切割(In-solution digestion)………………………26 第六節 TiO2親和性管住純化磷酸化胜肽……………………………………27 第七節 SILAC分析結果的蛋白差異鑑定……………………………………27 第八節 細胞生存能力試驗(MTT)…………………………………………27 第九節 傷口癒合試驗 (Wound healing assay)……………………………28 第十節 細胞侵襲試驗(Transwell assay)…………………………………28 第十一節 共免疫沉澱法(Co-immunoprecipitation)………………………29 第十二節 細胞核質分離法(Cell fractionation)………………………29 第四章 實驗結果……………………………………………………………………31 第一節 定量蛋白體標記穩定同位素胺基酸(SILAC)之結果分析…………31 1.1 HuH7和HuH7R細胞中差異磷酸化蛋白之功能分析………………31 1.2 HuH7與HuH7R細胞訊息傳導路徑分析……………………………32 1.3 胜肽基序(motif)分析………………………………………………32 1.4 利用火山圖(volcano plot)篩選目標蛋白………………………33 第二節 利用西方點墨法(western blotting)確認SILAC鑑定結果..34 2.1 YB-1在HuH7及HuH7R細胞中表現量之差異………………………34 2.2 YB-1在HuH7及HuH7R細胞中之訊息傳導路徑差異………………34 第三節 YB-1對細胞生理之功能分析(functional analysis)……………35 3.1 YB-1在HuH7細胞中之功能分析……………………………………35 3.2 以小髮夾RNA抑制YB-1進而探討YB-1在HuH7及HuH7R細胞中之功能………………………………………………………………………35 3.3 YB-1在YB-1 knock down HuH7R細胞中之功能探討………………36 第四節 YB-1之功能在HuH7R細胞中分子機制探討………………………37 4.1 探討活化態YB-1是否進入細胞核………………………………….37 4.2 確認AKT與YB-1是否有交互作用…………………………………37 4.3 YB-1影響HuH7R細胞轉移性(metastasis)之機制探討……………38 第五節 結論……………………………………………………………………38 第五章 討論…………………………………………………………………………40 第一節 實驗方法學討論……………………………………………………40 第二節 訊息傳導路徑研究之討論……………………………………………41 第三節 YB-1所調控之下游基因……………………………………………43 第四節 YB-1在癌症中扮演之角色討論……………………………………45 第五節 YB-1之藥物設計……………………………………………………46 第六節 結語與未來展望………………………………………………………47 第六章 參考文獻……………………………………………………………………49 圖表……………………………………………………………………………………53 | |
dc.language.iso | zh-TW | |
dc.title | 以定量磷酸化蛋白體分析找尋肝癌細胞在蕾莎瓦處理下所產生之替代訊息傳導路徑 | zh_TW |
dc.title | Quantitative Phosphoproteome Analysis to Reveal Alternative Signaling Pathways in Hepatocellular Carcinoma Cell under Sorafenib Treatment | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 徐立中(Li-Chung Hsu),蔡孟勳(Mon-Hsun Tsai) | |
dc.subject.keyword | 肝細胞癌,PI3K/AKT 訊息傳導路徑,替代訊息傳導路徑,蕾莎瓦,Y-box binding protein, | zh_TW |
dc.subject.keyword | Hepatocellular carcinoma,PI3K/AKT signaling pathway,Alternative signaling pathway,Sorafenib,Y-box binding protein, | en |
dc.relation.page | 75 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-08-20 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 3.68 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。